What is Meridian Bioscience?
Meridian Bioscience operates as a fully integrated life science enterprise, specializing in the development, manufacturing, and distribution of high-precision diagnostic and life science products. The company serves as a critical link in the global healthcare supply chain, providing essential raw materials for molecular and immunological testing. Its diverse portfolio includes advanced molecular platforms, immunoassay systems, and blood chemistry tools that address a wide spectrum of clinical needs, from respiratory and gastrointestinal diagnostics to tropical disease management. By maintaining a robust presence in over 70 countries, Meridian Bioscience leverages its Cincinnati-based headquarters to deliver scalable, accurate, and simplified diagnostic solutions to research centers, biotech firms, and healthcare providers worldwide.
How much funding has Meridian Bioscience raised?
Meridian Bioscience has raised a total of $525M across 2 funding rounds:
Other Financing Round
$25M
Debt
$500M
Other Financing Round (2022): $25M, investors not publicly disclosed
Debt (2023): $500M led by Standard Chartered, Standard Chartered Bank Ghana, Industrial Bank of Korea, J.P. Morgan Asset Management, Kookmin Bank, PNC Financial Services Group Inc, Citi, and Export-Import Bank of Korea
Key Investors in Meridian Bioscience
Standard Chartered
Standard Chartered plc is a British multinational banking and financial services company with an extensive network spanning over 70 countries.
Industrial Bank of Korea
A leading financial institution specializing in providing loans and comprehensive banking services to small and midsized enterprises across Asia and international markets.
J.P. Morgan Asset Management
A global financial services firm providing institutional-grade portfolio management and wealth advisory solutions with over 150 years of market expertise.
What's next for Meridian Bioscience?
The recent capital injection is expected to catalyze Meridian Bioscience's strategic initiatives, particularly in scaling its diagnostic manufacturing capabilities and accelerating the deployment of next-generation molecular platforms. As the company navigates the complexities of the global life science market, this financing provides the necessary runway to enhance its R&D pipeline and strengthen its international distribution network. Investors are likely to monitor how the firm utilizes these resources to maintain its competitive edge in the rapidly evolving diagnostic landscape, focusing on operational efficiency and the integration of new immunological technologies to meet increasing global demand for rapid, reliable testing solutions.
See full Meridian Bioscience company page
